Attovia Therapeutics Inc. jumped 29% in its trading debut, after the early-stage drug developer focused on immune system diseases raised $289 million in a US initia… The company’s shares ended at $21.90 each on Wednesday, above its IPO price of $17 apiece. The trading gives the company a market value of $942.3 million, based on the outstanding shares in its filings. ... We apologize, but this video has failed to load. Try refreshing your browser, or tap here to see other videos from our team. ... Attovia is developing drugs using a technology platform and patents licensed from Alamar Biosciences Inc., a maker of medical devices focused on studying proteins and disease detection. IPOs of biotechnology and pharmaceutical companies have been among the strongest performing new listings this year, led by pattern hair loss-focused Veradermics Inc.’s more than 550% increase since its debut in February and a 178% gain in the shares of blood disorder specialist Hemab Therapeutics Inc. (Bloomberg) — Attovia Therapeutics Inc. jumped 29% in its trading debut, after the early-stage drug developer focused on immune system diseases raised $289 million in a US initial public offering. Attovia’s IPO was led by Morgan Stanley, Leerink Partners, Citigroup Inc. and Royal Bank of Canada.